Arrowhead Pharmaceuticals Inc logo

ARWR - Arrowhead Pharmaceuticals Inc Share Price

$56.42 -0.7  -1.2%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £4.37bn
Enterprise Value £4.17bn
Revenue £129.1m
Position in Universe 1111th / 6416
Bullish
Bearish
Unlock ARWR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARWR Revenue Unlock ARWR Revenue

Net Income

ARWR Net Income Unlock ARWR Revenue

Normalised EPS

ARWR Normalised EPS Unlock ARWR Revenue

PE Ratio Range

ARWR PE Ratio Range Unlock ARWR Revenue

Dividend Yield Range

ARWR Dividend Yield Range Unlock ARWR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARWR EPS Forecasts Unlock ARWR Revenue
Profile Summary

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Directors
Last Annual September 30th, 2019
Last Interim September 30th, 2019
Incorporated February 13, 2001
Public Since December 14, 1993
No. of Shareholders: 112
No. of Employees: 134
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 100,106,271
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARWR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARWR
Upcoming Events for ARWR
Similar to ARWR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.